Pharmexa Discusses Results From Trial of HIV Vaccine

Pharmexa reported preliminary results from the Phase I trial of Pharmexa's epitope-based recombinant protein vaccine EP1043, which was tested alone and in combination with Pharmexa's DNA vaccine EP1090.

The HVTN 064 trial enrolled 84 healthy volunteers. The preliminary study analyses indicate the EP1043 protein vaccine is safe and well tolerated when administered alone or in combination with the EP1090.

Although the data are still blinded, it appears that the protein induces immune responses in the majority of vaccine recipients, with a response rate of approximately 80 percent in certain dose groups after two immunizations. There was no apparent synergistic effect with EP1090, Pharmexa reported.